PriceTracker GLP-1
Loading the index…

Try

Find the cheapest for me
Loading the index…

Try

GLP-1 TV · Clinician

Revolutionary Approach to Weight Loss - Zepbound (tirzepatide) Explained

Clinician3:57Nov 2023

Today’s cheapest Zepbound$348/mo at Lemonaid Health, medication and membership billed separately.Compare all Zepbound prices Price read 22 Nov 2026 from the seller’s own page, ranked by price alone. Not from the video’s creator.

Our summary

According to the video, Zepbound (tirzepatide) is a newly FDA approved weight management medication for obesity. The speaker describes it as the first dual incretin agonist, meaning it mimics two natural gut hormones and strengthens their action. It is given as a weekly injection. The speaker says that in meta analyses people taking it had an average body weight reduction of 22%, which the video calls a very high rate of weight loss.

Published by Dr. Constantin on YouTube

As published by the channel. Not medical advice, and not an endorsement.

What else the video covers

The middle of the video explains how the drug works. The speaker says Zepbound resembles two hormones released in the gut after eating, GLP-1 and GIP, and activates their receptors. According to the video, both hormones prompt the pancreas to release insulin when glucose is in the blood. GLP-1 slows gastric emptying, which the speaker says prolongs fullness and lowers calorie intake. The speaker also says both hormones promote the breakdown of fats for energy, raise metabolic rate, and reduce glucagon secretion, so the liver releases less glucose and blood sugar spikes are smaller. GLP-1 is also said to increase glucose transporter proteins so cells take up more glucose.

The final section covers use and limits. The speaker says it is indicated for a BMI above 40, for a BMI of 35 or higher with conditions such as diabetes, hypertension or cardiovascular disease, and for people with type 2 diabetes. The video names cost and limited long-term safety data as the main limitations. Listed side effects are abdominal discomfort, diarrhea, constipation and sometimes nausea, described as usually mild and temporary. The speaker says it is contraindicated with a history of pancreatitis or multiple endocrine neoplasia syndrome, and that there is no evidence it raises the risk of any cancer.

Our summary of what is said, in our words. Doses, results and prices are the speaker’s, not advice.

Takeaways

The main points, in the order they come up. Tap a time to play from there.

  1. 0:00 The speaker describes Zepbound as a weekly injection that mimics gut hormones to lower appetite and slow stomach emptying.
  2. 0:00 He cites meta analyses showing an average body weight reduction of 22%.
  3. 1:01 He explains that Zepbound mimics GLP-1 and GIP, which prompt insulin release and affect fat breakdown and blood sugar.
  4. 2:35 He lists the indications as a BMI above 40, a BMI of 35 or higher with comorbidities, and type 2 diabetes.
  5. 3:06 He names cost and limited long-term safety data as the main limitations, with mild, temporary digestive side effects.
  6. 3:36 He says it is contraindicated with a history of pancreatitis or multiple endocrine neoplasia syndrome, though no evidence shows increased cancer risk.

Key moments

Tap one to play from there.

  1. 0:00 Introduction
  2. 0:37 How it works
  3. 2:30 Indications

What the video says

As stated in the video, not checked by us. Doses and results are the speaker’s, not advice.

Medication
Zepbound and tirzepatide

Questions this video answers

How much weight do people lose on Zepbound?

According to the video, meta analyses show an average body weight reduction of 22%. The speaker calls this a very high rate of weight loss.

How does Zepbound work?

The speaker explains that it mimics the gut hormones GLP-1 and GIP. This prompts insulin release, slows gastric emptying so a person feels fuller longer, and promotes fat breakdown.

Who is Zepbound indicated for?

The video says it is indicated for a BMI above 40, for a BMI of 35 or higher with comorbidities such as diabetes, hypertension or cardiovascular disease, and for people with type 2 diabetes.

What are the side effects of Zepbound?

The speaker lists abdominal discomfort, diarrhea, constipation and sometimes nausea. He describes them as usually mild and temporary.

Videos on the same question

The closest videos in the library by what is said in them, not by title.

Read next

Our guides closest to what this video covers, with prices checked weekly.

  • What is Zepbound? Tirzepatide explained: what it treats, how it works, and what it costs

    Zepbound is Eli Lilly's brand of tirzepatide, a once-weekly injection that acts on two hormone receptors, GIP and GLP-1. The FDA label approves it, with diet and exercise, for weight reduction in adults with obesity or overweight plus a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. In the SURMOUNT-5 trial it produced 20.2% average weight loss at 72 weeks against 13.7% for semaglutide. Lilly sells it self-pay from $299 a month.

  • Mounjaro for weight loss, and why Zepbound exists

    Mounjaro is tirzepatide approved for type 2 diabetes. Zepbound is the same molecule from the same maker, approved for weight management, and it goes to the same 15 mg. So unlike Ozempic and Wegovy, there is no dose ceiling pushing you from one to the other: the reason people move is coverage and cash price, not strength. Using Mounjaro for weight is off-label and a prescriber's decision. In the one head-to-head trial, tirzepatide beat semaglutide, 20.2% mean body-weight loss at 72 weeks against 13.7%.

  • How to get Zepbound: who qualifies, who prescribes it, and the four ways to pay

    Zepbound is a prescription drug approved for adults with obesity, or overweight with at least one weight-related condition, which the trials defined as a BMI of 30, or 27 with a comorbidity. Any licensed prescriber can write it, including online. Then it is a payment question with four answers: a commercial plan that covers it brings it to $25 with Lilly's card; Lilly sells it direct for $299 to $699 a month by dose; a plan that refuses can be appealed; and compounded tirzepatide, which is not FDA-approved, starts at $69 on our board.

Next steps

Zepbound prices

Insurance

Find more like it

Side effectsDose changeFood noise and cravingsHow it works

Up next

More from this collection

Watched it? See what it costs.

Every GLP-1 program we track, ranked by what actually leaves your account.

Back to GLP-1 TV